OptiNose, Inc. provided preliminary unaudited earnings guidance for the three-month period ended March 31, 2024. For the period, the company expects to report approximately $14.9 million in net revenue from sales of XHANCE; a loss from operations of approximately $8.1 million; and a net loss of approximately $14.1 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.26 USD | +7.69% | +17.76% | -2.33% |
May. 20 | OptiNose, Inc. announced that it has received $4.68 million in funding | CI |
May. 14 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.33% | 182M | |
+48.53% | 780B | |
+41.04% | 627B | |
-6.37% | 353B | |
+20.93% | 334B | |
+8.21% | 296B | |
+17.53% | 244B | |
-1.06% | 217B | |
+11.33% | 214B | |
+4.40% | 161B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024